NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
April 29, 2024
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers
December 27, 2022
Related Post
-
-
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
April 26, 2024
-
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
April 26, 2024
-
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024